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ABSTRACT
Sarcoidosis has been rarely described in literature as a cause of interstitial pulmonary disease 
associated with AIDS. This study reports a case of immune reconstitution inflammatory syn-
drome associated with pulmonary sarcoidosis in a patient with a history of previous pulmonary 
tuberculosis concomitant with HIV infection. Results of the immunohistochemical study of 
samples from the resected right lower lobe are described. Pathological findings suggest a role 
of Th1, Th2 and Th17 response in IRIS associated sarcoidosis. 
Keywords: acquired immunodeficiency syndrome; sarcoidosis, pulmonary; immune reconstitution 
inflammatory syndrome; immunohistochemistry.
INTRODUCTION 
Sarcoidosis has been rarely described in litera-
ture as a cause of interstitial pulmonary disease 
associated with AIDS. The majority of cases have 
been related to immune restoration secondary to 
highly active antiretroviral therapy (HAART) in 
human immunodeficiency virus (HIV) infected 
patients.1 Association between CD4+ T lym-
phocyte count higher than 200 cells/mm³ and 
worsening of sarcoidosis course, as well as asso-
ciation between CD4+ less than 200 cells/mm³ 
and improvement of symptoms have been 
demonstrated in the literature.2
The clinical and pathological features 
of sarcoidosis in HIV-infected patients 
are similar to HIV-uninfected patients and 
have been reported after use of IL-2 
or IFN-alpha therapy in both HIV- 
infected patients and HIV-uninfected 
persons.3 Probably, immune reconstitution 
is associated with an immune dysregula-
tion that induces the Th1 immune responses 
against unknown antigens related to sar-
coidosis.3 
This is a diagnosis of exclusion, since 
several interstitial diseases, including gran-
ulomatous inflammation, occur in HIV-in-
fected patients, such as pulmonary disease 
due to Mycobacterium spp., Pneumocys-
tis jiroveci, Cryptococcus spp., Toxoplasma 
gondii, cytomegalovirus, Kaposi’s sarcoma, 
pulmonary nonspecific interstitial disease 
and lymphoid interstitial pneumonitis.1,3 
Immune reconstitution inflammatory syn-
drome (IRIS) may be defined as a paradoxical 
exacerbation of symptoms of opportunistic 
infections, inflammatory diseases or tu-
mours, in patients responding to antiretrovi-
ral therapy (ART), with decrease in plasma 
HIV RNA level by 1 log10 copies/mL.4 Minor 
criteria include increased blood CD4+ T cell 
after ART and improved specific immune 
response directed to a relevant pathogen or 
epitope. 
IRIS can induce sarcoid-like lesions in 
tissues within the first few weeks of initi-
ating therapy. The pathogenesis of these 
granulomas is currently unknown because no 
pathogen has been identified to date in the 
lesions using morphological and/or micro-
biological approaches.5 However, the role 
of certain microbes, such as Mycobacte-
rium tuberculosis, is still controversial in 
literature.5 
This study reports a case of pulmonary 
sarcoidosis related to IRIS in a patient with 
a previous history of pulmonary tubercu-
losis and concomitant HIV infection and 
describes the results of the immunohisto-
chemical evaluation performed in the resected 
lower lobe of the right lung of this pa-
tient. Informed consent was obtained from 
patient after explaning the study. Este é um artigo Open Access sob
 a licença de CC BY-NC-ND
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MATERIALS AND METHODS
A search with the terms “sarcoidosis” and “HIV” and “AIDS” 
was performed in PubMed, from 1966 to 2010, in order to 
find reported cases of this association. The data obtained was 
summarized by statistical analysis using the software SPSS 
10.0 for Windows (SPSS Statistics IBM, Chicago, IL, USA). 
Fragments of lung from the patient described in this study 
were stained by hematoxylin–eosin, Ziehl-Neelsen, Grocott 
and immunohistochemistry for Bacillus Camette-Guérin 
(BCG) from formalin-fixed, paraffin-embedded specimens.
Immunohistochemistry was performed in order to char-
acterize the composition of inflammatory cells in granulo-
mas with an indirect streptavidin–biotin complex immu-
noperoxidase technique on a DAKO TechMate (DAKO, 
Glostrup, Denmark). 
The following antibodies were employed: anti-CD20, 
CD14, CD4, CD8, CD14, CD57, CD68, toll like recep-
tor 2 (TLR-2), TLR-4, TLR-9, C3, FoxP3, TCRab, TNF-a, 
IFN-g, IL-1b, IL-2R, IL-4, IL-5, IL-6, IL-8, IL-10, IL-18, TGF-
b, and S100 (Dako, Glostrup, Denmark). Evaluation was per-
formed in 10 high power fields (i.e. field of vision at a magni-
fication of 1:400). The color intensity was controlled with an 
optical microscope using positive controls that accompany the 
reaction. Omission of the primary antibodies served as nega-
tive control. Times with washing buffer and incubations were 
followed strictly according to the manufacturer’s instructions.
CASE REPORT
A 29-year-old white male patient with a history of AIDS 
and pulmonary tuberculosis, diagnosed two years ago was 
admitted. The patient complained of daily evening fever rang-
ing from 38°C to 38.5°C, productive cough, weight loss of 
10 kg (normal was 70 kg) and progressive dispnea in the past 
six months. These clinical features began seven months after 
starting antiretroviral therapy with zidovudine, lamivudine 
and efavirenz, on a regular basis. 
Previous diagnosis of tuberculosis was based only in 
a positive sample of sputum for alcohol acid-fast bacilli 
(Ziehl-Neelsen technique) showing 1 to 10 bacilli per field in 
50 examined fields. He had been treated with isonyazid 400 mg, 
rifampin 600 mg and pyrazinamide 2,000 mg daily during 
two months followed by isonyazid 400 mg plus rifampin 
600 mg daily during four months and was discharged after 
having a negative sputum for alcohol acid-fast bacilli and 
improvement of symptoms at the end of treatment. 
CD4+ T cell count before starting antiretroviral 
therapy was 234 cells/mm³ and plasma HIV-1 RNA was 
34,564 copies/mL (branched-DNA technique), seven 
months before onset of symptoms. At admission, CD4+ 
count was 618 cells/mm³ and plasma HIV-1 RNA was 
undetectable (< 50 copies/mL). Despite the immune 
restoration, the patient presented three episodes of right 
lower lobe community acquired pneumonia, one of them 
complicated with empyema, within eight months before 
hospital admission. 
He also reported previous heterosexual exposure risk 
and past consumption of 80 g of alcohol per day for 11 years, 
but stated to have stopped drinking four years before . 
At admission, he had no changes on physical exami-
nation except for dyspnoea at rest, requiring nasal oxygen 
catheter at a flow rate of 2 L/min, digital clubbing and watch 
glass nails and auscultation with diminished breath sounds 
in the right pulmonary apex. There were no skin lesions. 
Arterial blood gas collected at room air revealed pH 7.26, 
pO2 = 50.8 mmHg, pCO2 = 53.1 mmHg, SO2: 79.3%, HCO3: 
23.7 mmol/L, base excess (BE):+3.9 mmol/L. Lactate dehy-
drogenase was 398 IU/L (normal range [NR] < 480 IU/L) 
and C-reactive protein was 3.16 mg/L (NR < 5 mg/L).
Assessment of delayed-type hypersensitivity response 
to tuberculin by a skin test turned out zero millimeter 
(response absent). Three samples of sputum and brochoal-
veolar lavage (BAL) were negative for mycobacteria and 
fungi in direct examination and culture.
Thoracic computed tomography (CT) scan revealed bi-
lateral pleural thickening, bilateral lung volume reduction 
in upper lobes, parenchymal distortion, bronchiectasis and 
thin-walled multiloculated cavities mainly in superior seg-
ment of the right lower lobe, diffuse areas of ground glass 
opacities in both lungs, as well as slight mediastinal para-
tracheal and subcarinal lymphadenopathy of about 1.3 cm, 
and increased caliber of the pulmonary artery and its main 
branches, consistent with pulmonary hypertension (Figure 1). 
There was no signal of pulmonary fibrosis. 
Figure 1: Chest CT revealed bilateral lung volume reduction 
due to upper lobes and parenchymal distortion, bronchiectasis 
and multiloculated cavities with thin walls over the upper 
lobes, and diffuse areas of ground glass opacities in both 
lungs.
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The electrocardiogram showed sinus rhythm, heart 
rate of 75 bpm, P and QRS waves with normal duration 
and voltages, normal QTc (400 ms) and signs of right 
ventricular overload probably due to arterial pulmonary 
hypertension: QRS axis of +180º, S1Q3T3 pattern, qR 
in V1, increased S wave in V5-V6 and rS in V2-V6. The 
echocardiogram was unable to estimate the pulmonary 
artery pressure due to poor acoustic window. 
The pulmonary function tests revealed severe re-
strictive defect: forced vital capacity (FVC) of 1.64 L 
(32% predicted), forced expiratory volume in one sec-
ond (FEV1): 1.37 L (33%), FEV1/FVC: 84%, and no im-
provement after bronchodilators.
The patient was submitted to a diagnostic and ther-
apeutic thoracotomy and right lower lobe resection. 
Material obtained showed diffuse bronchiectasis. The 
pathology report showed scattered noncaseating granu-
lomas forming clusters (sarcoid-like), with Langhans and 
foreign-body-type giant cells, around the bronchioles 
and vascular bundles, as well as areas of alveolitis, without 
evidence of Schaumann and asteroid bodies (Figure 2). 
Acid-fast stain and cultures for Mycobacterium spp. and 
fungi turned out negative. 
Abdominal CT scan and central nervous system 
(CNS) magnetic resonance imaging revealed no evi-
dence of sarcoidosis in the liver, spleen and CNS. 
Cerebrospinal fluid (CSF) analysis was also normal: one 
white blood cell per mm³ (55% lymphocytes and 10% 
monocytes), protein: 39 mg/dL (NR < 45 mg/dL) and 
glucose 80 mg/dL (NR: 50-90 mg/dL). Gram and acid-
fast stain as well as bacterial and fungal culture were all 
negative. Urinary calcium was of 435.2 mg/volume in 
24 hours (NR: 100-320 mg). Serum ionized calcium was 
normal: 4.7 mg/dL (NR: 4.6 to 5.3 mg/dL).
The patient was discharged with prednisone 30 mg 
daily (0.5 mg/kg), home oxygen therapy and hydroxy-
chloroquine 400 mg daily due to hypercalciuria. Six 
months thereafter the patient improved his dyspnea and 
pulmonary function: a 30% increase in FEV1 and FVC. 
A new thoracic CT three months after starting cortico-
therapy revealed reduction of thin-walled multiloculat-
ed cavities and diminished caliber of bronchiectasis in 
all lobes of both lungs, mainly in the left upper lobe. The 
response to corticosteroids and hydroxycloroquine was 
considered satisfactory. The patient continues to use the 
medication in outpatient setting and discontinued home 
oxygen therapy six months after.
RESULTS
Immunohistochemistry evaluation of the granulomas 
showed strong intensity of staining for IL-17 (Th17 re-
sponse) (Figure 3), dendritic cells (S100), macrophages 
(CD68), CD4+ T cell, CD8+ T cell, B cell (CD20), TCR-al-
pha/beta, IL-2R, IL-4 (Figure 4), TGF-beta, IL-10 and IL-12. 
Immunohistochemistry for IL-1 (Figure 5), IL-6, IL-8 and 
TNF-alpha showed strong staining both in granulomas 
and in alveolitis. There was a predominance of CD4+ T 
cell in alveolitis. Toll-like receptor-2 (TLR-2), TLR-4 and 
C3 showed a strong staining, but TLR-9 showed weak 
staining, as well as CD57 (NK cells), IFN-gamma and fork-
head-box transcription factor (FoxP3) both in granulomas 
and alveolitis (Figure 6). Grocott staining and immunohis-
tochemistry for BCG were negative (Figures 7 and 8).
Figure 2: Hematoxylin-eosin staining of resected lung segment 
from the patient, 100x magnification: clustered noncaseating 
granuloma around the terminal airways and areas of alveolitis. 
Search for infectious agents resulted negative.
Figure 3: Immunohistochemistry for IL-17, marker of Th17 
response, showed strong staining in granulomas and alveoli 
(400x magnification). 
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DISCUSSION
This case presents a stage III pulmonary sarcoidosis in a 
white man, characterized by pulmonary hypertension and 
obstructive and restrictive ventilatory impairment, begin-
ning seven months after the introduction of antiretroviral 
therapy. Thoracic CT scan showed an atypical pattern sug-
gestive of alveolar filling, probably due to the IRIS. Clinical 
evolution characterized by good response to corticosteroids 
and repeated negative search for infectious agents reinforced 
this hypothesis.
There were 55 cases of AIDS and sarcoidosis association 
in international literature, 14 of those before the HAART 
era, based on a positive Kveim-Stilzbach test in AIDS pa-
tients.1,6-19 All cases ruled out infectious agents and dem-
onstrated sarcoidosis by anatomopathological findings. 
Figure 4: Immunohistochemistry for IL-4, marker of Th2 
response, showed strong staining in granulomas and alveoli 
(400x magnification). 
Figure 5: Immunohistochemistry for IL-1-beta, marker of Th1 
response, revealed strong staining in the core of granulomas 
(400x magnification). This cytokine was also detected in 
alveolitis.
Figure 6: Immunohistochemistry for FoxP3, marker of Treg 
response, revealed weak staining in the core of granulomas 
(400x magnification). 
Figure 7: Grocott staining (400x magnification): search for 
fungi was negative.
Figure 8: Immunohistochemistry for bacillus Calmette-Guerin 
(BCG) was negative (400x magnification).
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Two of these patients presented the symptoms after ther-
apy with IL-2. The median of time between antiretro-
viral therapy and onset of symptoms of sarcoidosis was 
9 months (95% CI: 5.63–13.19 months), ranging from 0 to 
48 months, longer than IRIS associated with granuloma-
tous infectious diseases (few weeks). The median age was 
37 years (interquartile range [IR]: 12.5 years) and 59.1% 
were male. The median CD4+ nadir before symptoms was 
11 cells/mm³ (IR: 197/mm³) and at onset of symp-
toms, CD4 count was 341 cells/mm³ (IR: 272 cells/mm³) 
(p < 0.05, Wilcoxon test). Median highest plasma viral 
load before symptoms was 9,400 copies/mL (IR: 36,123 
copies/mL) and during the event was < 50 copies/mL 
(p < 0.05, Wilcoxon test). The CD4:CD8 ratio on bron-
coalveolar lavage was 3.37 (± 3.01). Dispnea was the most 
frequent symptom (32.7%), followed by constitutional 
symptoms (23.5%), skin disease (13.7%) and lymphad-
enopathy (12%). Three patients were asymptomatic. 
Foulon et al.,7 found abnormal pulmonary function test 
in four of 11 patients, with a restrictive pattern in three 
and an obstructive pattern in one. Clinicopathologi-
cal features were similar between HIV-uninfected and 
HIV-infected patients.1,6-19 
The radiological stage II of pulmonary sarcoidosis was 
the most frequent (33.3%), followed by stage I (25.5%) and 
stage III (15.7%). The evolution was unfavorable in 7.8% of 
these patients, characterized by poor response to treatment. 
No death due to IRIS associated with sarcoidosis was de-
scribed in the literature. 
Haramati et al.16 described thoracic CT findings in 
eight patients with IRIS associated with sarcoidosis in HIV 
patients: peribronchovascular and subpleural nodules and 
mediastinal lymphadenopathy were the most frequent find-
ing. Ground glass opacities were observed in four of these 
patients. No association between the radiographic features 
of sarcoidosis and the CD4+ cell count was found. 
Data from the literature are similar to findings of this 
case. The disease presented a worsening of symptoms as-
sociated with restoration of immune response following 
antiretroviral therapy. The magnitude of immune restora-
tion may be demonstrated by the difference between CD4+ 
counts both in the case described here and in 55 cases from 
the literature. Infectious agents and other causes of intersti-
tial pulmonary disease were always ruled out. 
This is the first study in literature of immunohistochem-
istry in an HIV patient with IRIS-associated sarcoidosis. 
Pathological findings suggest a role of Th1 and Th2 response 
and imbalance of Treg/Th17, as well as role of complement, 
TLR-2 and 4 (innate immunity), in the pathogenesis of IRIS 
associated with sarcoidosis in this patient. 
IRIS is characterized by replenishment of immune cells 
depleted by HIV infection, circulating of immune cells situ-
ated in compartments of the immune system, regeneration 
of lymphoid organs and recovery of pathogen or antigen-
specific T, B, and NK response, diversity of response and 
regulation of the reconstituted immune system.3 The anti-
gen-specific Th1 (granulomatous inflammation) and Th17 
(suppurative inflammation) response, augmented against 
mycobacteria, fungi and protozoans in the context of 
IRIS,3 is also associated to sarcoidosis in this case report. 
Described in literature as a response that causes genesis 
and perpetuation of the inflammatory response,20 Th17 
cytokines are depleted in progressive lentiviral disease, 
characterized by loss of Th17/Treg balance.21
However, the patient has reduced expression of FoxP3 
in granulomas, probably a marker of a diminished role 
of Treg response in the tissue affected by IRIS associated 
with sarcoidosis. This response has been implicated as a 
cause of peripheral anergy, but in pulmonary granulomas 
it has been associated to remission of fibrosis.22,23 Shift Th1 
to Th2 response in sarcoidosis is associated to progressive 
fibrosis,22,23 characteristic not found in this patient. It was 
demonstrated in literature this shift in the progression of 
HIV infection.24 
Conflicting findings were the weak expression of IFN-
gamma in this immunohistochemical study and normal 
serum level of C-reactive protein, which is described in 
the literature as a marker and a predictor of IRIS.25 Further 
studies are needed to explain these findings. 
CONCLUSION
Considering all the clinic, radiology, laboratory and 
pathology data, this case presents a well described im-
mune-reconstitution associated with sarcoidosis and 
suggests a possible role of Th1 and Th17 response in this 
syndrome. Further studies with larger samples are needed to 
confirm and explain the pathophysiology of these findings.
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